BTIG, Inari
Jonathan Krinsky, chief market technician at BTIG, joins CNBC's 'The Exchange to discuss his outlook on stocks for 2025, what ...
BTIG Life Sciences and Diagnostic Tools Analyst Massaro holds group dinner meeting with CEO Stueland and CFO Feeley on January 13 at 10:30 am.
24/7 Wall St. on MSN3d
Large-Cap Value Stocks Could Rule in 2025: 4 High-Yield Dividend WinnersHere are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...
BTIG is growing its transition management business and hired a senior executive to help boost business. The firm has hired Daniel Howell as a director who will be based in New York. His job is ...
Last week, BTIG analyst Jake Fuller reiterated a Buy rating on Uber Technologies (UBER) stock with a price target of $90. The analyst remains bullish on the ride-hailing company but expects its Q4 ...
“In 2025, the energy sector will be less about barrels of oil and more about...billions of cubic feet of natural gas demand ...
The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...
BTIG analyst Jake Fuller says that while Uber‘s (UBER) commentary on its U.S. rideshare business “felt constructive” at intra-quarter appearances, the firm’s receipt data was “more ...
BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...
BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback